Jilin Xianfeng Technical Pharmaceutical Co., Ltd.

This product is a hypoglycemic drug. 1. It stimulates the pancreatic islet beta cells to secrete insulin, which presupposes that the islet beta cells also have a certain ability to synthesize and secrete insulin; 2. It inhibits liver glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or directly acting on the liver, and reduces the generation and output of glucose in the liver; 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to reduce fasting blood sugar and postprandial blood sugar.

It is a glycoside of dehydrogenated flavonoids, which often coexists with vitamin C in food. It may participate in the action of oxidoreductase in the body, affect the activity of the thyroid gland, and protect adrenaline from oxidation. In the body, it can enhance the effect of vitamin C and promote its accumulation in the body, maintain vascular elasticity, enhance capillary resistance, reduce its fragility and permeability, and promote its cell proliferation and prevent blood cell aggregation.

It is a hydrogen transmitter and may be involved in the action of oxidoreductase in the body. It can affect the activity of the thyroid gland and protect adrenaline from oxidation. In the body, it can enhance the effect of vitamin C and promote its accumulation, maintain vascular elasticity, enhance capillary resistance, reduce its fragility and permeability, promote cell proliferation and prevent blood cell aggregation.

Antibacterial, antiviral, antipyretic and anti-inflammatory effects

Antibacterial, antiviral, antipyretic and anti-inflammatory effects

Antibacterial, antiviral, antipyretic and anti-inflammatory effects

Antibacterial, antiviral, antipyretic and anti-inflammatory effects

Antibacterial, antiviral, antipyretic and anti-inflammatory effects

This product is a gastrin receptor antagonist, which can significantly inhibit the secretion of gastric acid and pepsin caused by gastrin, but has no obvious effect on the gastric acid secretion caused by histamine and vagus nerve stimulation. It can increase the content of hexosamine in the gastric mucosa, promote glycoprotein synthesis, protect the gastric mucosa and promote healing, improve the symptoms of peptic ulcer and promote ulcer healing. The use of this product to treat peptic ulcer and gastritis does not cause rebound of gastric acid secretion, and gastric acid secretion can remain at a normal level for up to half a year after the treatment is terminated. In addition, this product has a choleretic effect, preventing stone formation and promoting bile duct health by stimulating bile acid-independent bile secretion, changing the stone-forming factors in bile, and antagonizing CCK.